Ocular Therapeutix

Update in progress

OCUL (NasdaqGM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Ocular Therapeutix, Inc. is a biopharmaceutical company applying bioresorbable hydrogel formulations to eye diseases in the United States. It markets DEXTENZA, a dexamethasone ophthalmic insert for post-surgical inflammation and pain, and allergic conjunctivitis. It is developing AXPAXLI (axitinib) in Phase 3 for wet AMD and NPDR, and OTX-TIC (travoprost) in Phase 2 for open-angle glaucoma/ocular hypertension. Licensed with AffaMed. Founded 2006, based in Bedford, MA.

Company score

Sentiment: 0.34; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.24; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.11; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.09; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.21; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive

Company

MarketNasdaqGM (NGM)
LocationUnited States
CEODr. Pravin U. Dugel M.D.
Founded2006
Employees325
Websitewww.ocutx.com

Identifiers

ISINUS67576A1007
FIGIBBG001J1BZV0
LEI529900ABAWFXOHSIHG03
CUSIP67576A100
CIK0001393434